Price fixing: PBMs push for lower prices of PCSK9 inhibitors

Now that the first two PCSK9 inhibitors have been given the thumbs-up by the FDA, the payer community finds itself in a situation comparable to the one it faced upon the arrival of transformative hep.-C drugs: What are they prepared to pay—and which drugs will get the formulary nod? Jaimy Lee assesses the fluid market dynamics http://www.mmm-online.com/price-fixing-pbms-push-for-lower-prices-of-pcsk9-inhibitors/article/439375/ 9/21/2015 15:00:00